ANALYSIS OF THE POPULATION'S READINESS TO INCLUDE VACCINATION AGAINST DISEASES CAUSED BY THE HUMAN PAPILLOMAVIRUS IN THE NATIONAL CALENDAR OF PREVENTIVE VACCINATIONS: LITERATURE REVIEW
Introduction: Vaccination against human papillomavirus (HPV) is a major public health strategy for cervical cancer prevention by reducing the incidence of HPV infection in the general population. In addition to screening, it offers a powerful tool to significantly reduce the global burden of cervical cancer. A judicious combination of vaccination and screening can potentially eliminate cervical cancer in vaccinated populations. The vaccine is highly effective against high-grade precursors of vulvar, vaginal and anal cancers in women, offering comprehensive protection against malignant tumors of the anogenital tract in women. There are now two HPV vaccines available in the markets of many countries - bivalent and tetravalent. Both vaccines are highly effective in preventing infection with viruses types 16 and 18, which together account for 70% of cervical cancers worldwide. Clinical trials and primary post-marketing surveillance data from several continents demonstrate the safety of both vaccines. In most countries, the primary target group with a positive HPV immunization response is adolescent girls between the ages of 9 and 14. The immunization schedule for both vaccines depends on the age of the vaccine recipient.
Objective: to study the organization of vaccination against human papillomavirus in the Republic of Kazakhstan and in the world.
Search strategy: The sources were searched in the following databases: Pubmed, Scopus, Ebscohost, Medline, The Corrane Library, Cyberlininka, Google Academy. The search depth was 10 years: from 2011 to 2021. Inclusion criteria were: reports of randomized and cohort studies conducted on large populations; meta-analyses and systematic reviews; articles in English and Russian, full-text articles, full-text articles with free access. The exclusion criteria were: articles describing single cases and series of cases; articles, materials that do not have an evidence base, summaries of reports, abstracts and newspaper articles. 138 articles were found on this topic, of which 52 articles were included.
Results: A literature review showed that human parilloma virus is associated with a large number of diseases leading to disability and mortality in both women and men; vaccination against HPV has confirmed its effectiveness and safety in all countries that have included it in their National Programs;
Conclusions: An integrated approach is needed to increase vaccination coverage against human papillomavirus. It is important to raise awareness among adolescents, parents and healthcare providers as target audiences for vaccination.
Mamyr S. Torebekova1, Assel Zh. Baibussinova1, Yerbol M. Smail1, Bakytkul' Zh. Toktabaeva1, Zhanar M. Zhumanbayeva1
NCJSC «Semey Medical University», Semey city, the Republic of Kazakhstan.
1. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К., Вишнева Е.А., Федосеенко М.В., Селимзянова Л.Р. др. Руководство по профилактике заболевания/синдромов. Вакцинопрофилактика заболеваний, вызванных вирусом папилломы человека. Москва: Министерство здравоохранения Российской Федерации, Союз педиатров России, 2017, 25с.
2. Бруснигина Н.Ф. Махова М.А., Орлова К.А., Колесникова Е.А., Черневская О.М., Барышева Н.Н. Пейзаж генотипов папилломавирусов,циркулирующих среди женщин Нижнего Новгорода // Молекулярная диагностика. 2017. Т1: 119-120.
3. Государственный реестр лекарственных средств Гардасил. Инструкция по применению (Өтініш берген күн 26.01.2022): http://www.grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=10f1f54f-78d1-4b34-a0a1-52d981b8c040&t=b05928ee-e67c-4130-b488-d4f26ab99f3f. (accessed 21.01.2022)
4. Зароченцева Н.В., Белая Ю.М., Самсыгина Г.А., Щербакова М.Ю., Выжлова Е.Н., Малиновская В.В. Папилломавирусная инфекция и ВПЧ ассоциированные заболевания // Лечащий врач. 2017; Т. 4. С. 115-125.
5. Зароченцева Н.В., Белая Ю.М. Опыт реализации программ первичной профилактики заболеваний, вызываемых вирусом папилломы человека, в Московской области // Эпидемиология и вакцинопрофилактика. 2017, 6(97): 59-65.
6. Касаткин Е.В., Лялина Л.В. Гендерные различия распространенности папилломавирусной инфекции, обусловленной вирусом высокого канцерогенного риска среди пациентов дерматовенерологического профиля // Дерматология в России. 2017: 47
7. Ключарева С.В., Ядыкин А.А. Проблемы лечения папилломавирусной инфекции и пути решения // Клиническая дерматология и венерология. 2010. 5: 9–16.
8. Олюнина Е.А., Дуванова Е.А., Николаева Т.Н. Исследование циркуляции вируса папилломы человека 16 и 18 типов // Молекулярная диагностика. 2017; 1 (6): 102–103.
9. Сайт Всемирной организации здравоохранения https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer (accessed: 22.01.2022).
10. Ali H., Donovan B., Wand H., Read T.R.H., Regan D.G., Grulich A.E. et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data // BMJ. 2013. 346:f2032.
11. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R. et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia // Vaccine. 2008. 26S: K1–K16
12. Canvin M., Sinka K., Hughes G. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017. 2: 93:125–128.
13. Chow E.P.F. Machalek D.A., Tabrizi S.N., Danielewski J.A. et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study // The Lancet Infectious Diseases. 2017. 1: 17: 68-77.
14. Drolet M. Bénard E., Pérez N., Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis // The Lancet. (accessed: 26.01.2022): https://www.thelancet.com/action/showPdf?pii=S0140-6736%2819%2930298-3
15. European Medicines Agency Гардасил, характеристика препарата - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000703/WC500021142.pdf (accessed: 26.01.2022).
16. European Medicines Agency Научная дискуссия, Гардасил. -http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000703/WC500021140.pdf(accessed: 26.01.2022)
17. European Medicines Agency. Гардасил 9, характеристика препарата. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/003852/WC500189111.pdf (accessed: 26.01.2022)
18. European Medicines Agency: Церварикс, характеристика препарата. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000721/WC500024632.pdf (accessed: 26.01.2022).
19. Esquerre M., Bouillette-Marussig M. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T-cell responses leading to tumor regression // PLoS One 2017; 12 (3): e0174038.
20. FDA GARDASIL®9. - https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm426457.pdf. (accessed: 26.01.2022)
21. Franceschi S., Chantal Umulisa M., Tshomo U., Gheit T., Baussano I., Tenet V. et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda // International Journal of Cancer. 2016. 3 : 139: 518–526
22. Gavi, the Vaccine Alliance Support https://www.gavi.org/support/. (accessed 26.01.2022).
23. GAVI: The Vaccine Alliance Country Hub [Электронный ресурс]. (accessed: 26.01.2022) http://www.gavi.org/country/
24. GAVI: The Vaccine Alliance. HPV. Countries approved for support. (accessed: 26.01.2022) http://www.gavi.org/results/countries-approved-for-support/.
25. Garland S.M. Kjaer S.K., Muñoz N., Block S.L., Brown D.R., Dinubile M.J. et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience // Clinical Infectious Diseases. 2016. 63: 519-527.
26. Hall M.T., Simms K.T., Lew J. Bin. The projected timeframe until cervical cancer elimination in Australia: a modelling study // The Lancet Public Health. 2019. -4: 1: e19-e27.
27. Hariri S., Bennett N.M., Niccolai L.M., Schafer S., Park I.U., Bloch K., Unger E.R., Whitney E., Julian P., Scahill M.W. et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008 - 2012 // Emerg Infect Dis. 2015. 13: 33: 1608-1613.
28. Harper D.M. HPV vaccines – Review of the first decade // Gyn Onc 2017; 146: 196–204
29. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Russian Federation. Summary Report 7 October 2016. (accessed: 30.12.2022)
30. Information Centre on HPV and Cancer Rwanda. Human Papillomavirus and Related Diseases Report: HPV Information Centre, 2017, 65p
31. Joura E.A. et al. Suppl. disease. Abstract MSS 2–5 presented at EUROGIN Seville, Spain // N Engl J Med 2015. 372: 711–23. 2015.
32. Joura E.A., Kyrgiou M., Bosch F.X., Kesic V., Niemenen P., Redman C.W., Gultekin M. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy // The European Journal of Cancer. 2019. 116: 21-26.
33. Lowy D.R. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions // J. Clin. Invest. 2016. Vol. 126, N 1. P. 5–11.
34. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G. et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Healt and Nutrition Examination Surveys // J Infect Dis. 2013. 3 : 208: 385-93.
35. Merck & Co. Inc. GARDASIL®. Prescribing information (accessed: 26.01.2022) -https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf.
36. Mesher D., Panwar K., Thomas S.L, Beddows S., Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study // BMJ Open. 2016. 2 : 6. e009915.
37. Ngabo F., Franceschi S., Baussano I., Umulisa M.C., Snijders P.J.F., Uyterlinde A.M. et al. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme // BMC infectious diseases. 2016. 16. 225.
38. Ogilvie G.S. Naus M., Money D.M., Dobson S.R., Miller D., Krajden M. et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis // Int J Cancer. 2015. 8: 137: 1931–7.
39. PAHO revolving fund. (accessed 26.01.2022) http://www.paho.org/hq/index.php?option=com_content&view=article&id=91&Itemid=220&lang=en.
40. Palmer T., Wallace L., Pollock K. G. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study // BMJ. 2019. 1161: 365.
41. Pollock K.G.J., Kavanagh K., Potts A., Love J., Cuschieri K., Cubie H. et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland // Br J Cancer. 2014. 9: 111: 1824–30
42. Powell S.E. Hariri S., Steinau M., Bauer H.M., Bennett N.M. et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesion // Vaccine. 2015. 1: 31: 109–113
43. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines, 6th edition: Elsevier Ltd, 2013, 1570p.
44. Saraiya M., Unger E.R., Thompson T.D., Lynch C.F. et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines // J. Natl Cancer Inst. 2015.Vol. 107, N 6. Article ID djv086
45. Smith L.M. Strumpf E.C., Kaufman J.S., Lofters A., Schwandt M., Lévesque L.E. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts // Pediatrics. 2015. 5: 135: 1131-1140.
46. Steben M. Review of the impact and effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada // J Obstet Gynaecol Can 2018; 40 (12): 1635–45.
47. Steben M. ,Tan Thompson M., Rodier C., Mallette N., Racovitan V., DeAngelis F., Stutz M., Rampakakis E. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada // Journal of Obstetrics and Gynaecology Canada. 2018. 12 : 40: 1635-1645.
48. Shrestha A.D., Neupane D., Vedsted P., Kallestrup P. Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review // Asian Pac J Cancer Prev. 2018. 2 : 19: 319–24.
49. Tshomo U., Franceschi S., Dorji D., Baussano I., Tenet V., Snijders P.J. et al. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme // BMC Infect Dis . 2014. 1: 14: 408.
50. Unicef Human Papillomavirus Vaccine Supply & Demand Update. 2015.6p.
51. Wang B., Giles L., Afzali H.H.A., Clarke M., Ratcliffe J., Chen G., et al. Adolescent confidence in immunisation: Assessing and comparing attitudes of adolescents and adults // Vaccine. 2016. 46: 34. 5595–5603.
52. Respublikanskii tsentr razvitiya zdravookhraneniya http://www.rcrz.kz/.pdf (accessed: 21.01.2022)
References: [1-9]
1. Baranov A.A., Namazova-Baranova L.S., Tatochenko V.K., Vishneva E.A., Fedoseenko M.V., Selimzyanova L.R. dr. Rukovodstvo po profilaktike zabolevaniya/sindromov. Vaktsinoprofilaktika zabolevanii, vyzvannykh virusom papillomy cheloveka [Guidelines for the prevention of disease/syndromes. Vaccination of diseases caused by the human papillomavirus]. Moskva: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, Soyuz pediatrov Rossii, 2017, 25p. [in Russian]
2. Brusnigina N.F., Makhova M.A., Orlova K.A., Kolesnikova E.A., Chernevskaya O.M., Barysheva N.N., Peizazh genotipov papillomavirusov, tsirkuliruyushchikh sredi zhenshchin Nizhnego Novgoroda [Landscape of papillomavirus genotypes circulating among Nizhny Novgorod women]. Molekulyarnaya Diagnostika [Molecular diagnostics]. 2017, T1: 119-120p.[in Russian]
3. Gosudarstvennyi reestr lekarstvennykh sredstv Gardasil. Instruktsiya po primeneniyu. http://www.grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=10f1f54f-78d1-4b34-a0a1-52d981b8c040&t=b05928ee-e67c-4130-b488-d4f26ab99f3f. (accessed: 26.01.2022): [in Russian]
4. Zarochentseva N.V., Belaya Yu.M., Samsygina G. A., Shcherbakova M. Yu., Vyzhlova E. N., Malinovskaya V. V., Papillomavirusnaya infektsiya i VPCh assotsiirovannye zabolevaniya [Papillomavirus infection and HPV-associated diseases]. Lechashchii vrach [Attending physician] 2017; T. 4 [in Russion]
5. Zarochentseva N.V., Belaya Yu.M., Opyt realizatsii programm pervichnoi profilaktiki zabolevanii, vyzyvaemykh virusom papillomy cheloveka, v Moskovskoi oblasti [Experience in implementing programs of primary prevention of diseases caused by the human papillomavirus, v Moskovskoi oblasti]. Epidemiologiya i vaktsinoprofilaktika [Epidemiologiya i vaktsinoprofilaktika]. 2017, 6(97): 59-65p. [in Russian]
6. Kasatkin E.V., Lyalina L.V., Gendernye razlichiya rasprostranennosti papillomavirusnoi infektsii, obuslovlennoi virusom vysokogo kantserogennogo riska sredi patsientov dermatovenerologicheskogo profilya [Gender differences in the prevalence of papillomavirus no and infection caused by a high-risk carcinogenic virus among dermatovenerological patients]. Dermatologiya v Rossii [Dermatology in Russia]. 2017: 47p [in Russian]
7. Klyuchareva S.V., Yadykin A.A., Problemy lecheniya papillomavirusnoi infektsii i puti resheniya [The problem of treating papillomavirus is not both an infection and a solution]. Klinicheskaya dermatologiya i venerologiya [Clinical dermatology and venereology]. 2010. 5: 9–16p. [in Russian]
8. Olyunina E.A., Duvanova E.A., Nikolaeva T.N., Issledovanie tsirkulyatsii virusa papillomy cheloveka 16 i 18 tipov [Investigation of the circulation of human papillomavirus types 16 and 18]. Molekulyarnaya diagnostika [Molecular diagnostics]. 2017; 1 (6): 102–103p. [in Russian]
9. Sait Vsemirnoi organizatsii zdravookhraneniya [World Health Organization website]. https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer (accessed: 22.01.2022). [in Russian]
Number of Views: 132
Category of articles:
Reviews
Bibliography link
Torebekova M.S., Baibussinova A.Zh., Smail Ye.M., Toktabaeva B.Zh., Zhumanbayeva Zh.M. Analysis of the population's readiness to include vaccination against diseases caused by the human papillomavirus in the national calendar of preventive vaccinations: literature review // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 2, pp. 183-192. doi 10.34689/SH.2022.24.2.022Related publications:
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
QUALITY OF LIFE IN PRIMARY BILIARY CHOLANGITIS AND ITS ASSESSMENT
DIAGNOSTIC AND THERAPEUTIC LAPAROSCOPY FOR ABDOMINAL INJURIES. REVIEW
METHODS FOR SCHOOL-AGE CHILDREN NUTRITIONAL STATUS ASSESSMENT: FOCUS ON ANTHROPOMETRIC PARAMETERS. A REVIEW.